# CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation

> **NCT02893189** · PHASE1 · COMPLETED · sponsor: **University College, London** · enrollment: 17 (actual)

## Conditions studied

- CD19+ Malignancies: Relapse Post-allogeneic Transplant

## Interventions

- **GENETIC:** Infusion of modified CAR19 T-cells (4G7-CARD T-cells)

## Key facts

- **NCT ID:** NCT02893189
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-27
- **Primary completion:** 2019-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02893189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02893189, "CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02893189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*